

Determination of remifentanyl in neonatal dried blood spots by liquid chromatography-tandem mass spectrometry

JURIJ TRONTELJ^{1,*}
ALEŠ ROZMAN²
ALEŠ MRHAR¹

¹ University of Ljubljana
Faculty of Pharmacy
1000 Ljubljana, Slovenia

² Gynecology and Obstetrics
Hospital Kranj, 4000 Kranj
Slovenia

ABSTRACT

Remifentanyl is an ultra-short-acting synthetic opioid-class analgesic which might be increasingly used “off-label” as pain management during labour. Side effects in parturients during labour, and in the infant at birth are of particular concern, especially respiratory depression which is concentration-dependent, and can occur at levels as low as 3–5 ng mL⁻¹. The safety of such use, particularly in newborns due to remifentanyl placental transfer, has not been fully demonstrated yet, partly due to the lack of a suitable non-invasive analytical method. The aim of our work was to develop a sensitive method to monitor the levels of remifentanyl in neonates by a non-invasive sampling of umbilical cord blood to support efficacy and safety trials. The presented LC-MS method is sensitive enough to reliably quantify remifentanyl in just 20 µL of blood at only 0.3 ng mL⁻¹. The dried blood spot sample preparation included solvent extraction with subsequent solid-phase extraction. The method was validated in terms of accuracy, precision, recovery, matrix effect, and stability, and was successfully applied to a small pilot study. The estimated arterial blood concentrations at the time of delivery ranged from 0.2 to 0.3, and up to 0.9 ng mL⁻¹ in neonatal, and maternal samples, respectively.

Keywords: remifentanyl, patient-controlled analgesia, labour, dried blood spots, umbilical cord blood

Accepted March 28, 2024
Published online March 28, 2024

INTRODUCTION

Remifentanyl is a synthetic opioid-class analgesic with an ultra-short duration of action. It is given intravenously and is very quickly cleaved by plasma- and tissue-esterases to inactive remifentanyl acid, resulting in an extremely short remifentanyl biological half-life of only 3–10 min (1). It is being used as an analgesic for pain management during anaesthesia, and in intensive care units because of its rapid initiation and subsequent termination of the action. It is also being increasingly used “off-label” as pain management during labour. The recent draft guidelines by the National Institute for Health and Care Excellence (NICE) recommend remifentanyl for parturients who do not want epidural anaesthesia (2). For this purpose, a patient-controlled analgesia system (PCA) is often used, where the

*Correspondence, e-mail: jurij.trontelj@ffa.uni-lj.si

parturient can administer bolus doses from 0.15 up to 0.9 $\mu\text{g kg}^{-1}$ of remifentanyl before each contraction with or without concomitant basal infusion (of up to 0.05 $\mu\text{g kg}^{-1} \text{min}^{-1}$) (3–5). However, the recent protocols usually include bolus doses of 20 to 40 μg , depending on parturient weight, with one to two-minute lockout periods (6, 7).

Adverse drug reactions may include dose-dependent and plasma concentration-dependent hypotension, bradycardia, muscle rigidity, and respiratory depression. Blood concentrations of 1–3 ng mL^{-1} are considered analgesic with minimal (but nevertheless possibly present) effects on ventilation. Spontaneous ventilation occurs at 4–5 ng mL^{-1} (1). A study on remifentanyl PCA administration during labour reported maternal remifentanyl plasma levels of approximately 5 ng mL^{-1} (8). According to the manufacturer, when the concentration exceeds 5 ng mL^{-1} , transient respiratory depression, apnea, and muscle rigidity can occur (1). Furthermore, remifentanyl rapidly crosses the placenta, and its pharmacokinetic and pharmacodynamic profile may be different from that of an adult (9).

Nevertheless, the theoretical and reported growing practical evidence speaks in favour of safe remifentanyl use during labour if the established standard procedure is followed, as was recently reported by the authors from RemiPCA SAFE Network (5). Although many obstetric clinics already routinely offer an option of remifentanyl as the most effective alternative technique to epidural analgesia (10), a clear consensus about its safe applicability for this indication has not been reached (11, 12), and additional research is necessary to determine the safety of remifentanyl treatment during labour (13).

Even though the parturient heart and ventilatory function or saturation must be constantly monitored by an anaesthesiologist, some cases of respiratory arrest in mothers have been associated with remifentanyl use during labour (14–18). Moreover, the short- and long-term effects on infants caused by remifentanyl use during labour have not been fully characterised either (19, 20).

Therefore, more trials are needed to better elucidate remifentanyl pharmacokinetic and pharmacodynamic profiles in both the mother and the child to provide the optimal dosing regimen in terms of reaching the best compromise between efficacy and safety.

To support such trials, a suitable analytical method for remifentanyl blood levels is required, where the analyte stability is not compromised after blood withdrawal due to hydrolysis of the ester bond by plasma esterases in obtained samples (Fig. 1). An additional requirement is that the method would require only small volumes of blood samples, suitable for neonatal monitoring. Ideally, the sampling could be obtained as dried blood spots, since this is a long-established routine technique for neonatal screening. Furthermore, the dried blood spots can be obtained from umbilical cord blood, minimizing the




Fig 1. The chemical structure of remifentanyl, with the arrow pointing to the ester bond subjected to enzymatic cleavage during its rapid elimination from blood.

burden for the newborn, and at the same time, getting also the most relevant sample for determination of true remifentanil concentration in the newborn at the time of cord clamping. Recently, a method for the determination of 132 psychoactive compounds in dried blood spots has been reported, which included also remifentanil (21), but with a limit of quantitation of 5 ng mL^{-1} , it lacks the sensitivity needed to assess the levels possibly leading to the adverse drug effects in newborns and their mothers, which can start to occur already at $1\text{--}3 \text{ ng mL}^{-1}$.

Accordingly, the aim of our study was to develop a rapid and sensitive method for the determination of remifentanil in dried umbilical cord blood spots to support the efficacy and safety trials of remifentanil during labour, with a limit of quantitation below the threshold of 1 ng mL^{-1} , where the adverse effects may start to appear.

EXPERIMENTAL

Materials

Remifentanil and isotopically labelled internal standard remifentanil- $^{13}\text{C}_6$ (IS) have been purchased from Toronto Research, Canada.

Blank dried blood spot cards Whatman 903 have been obtained from GE Healthcare Bio-sciences Corp. Piscataway, NJ, ZDA.

Blank pooled human blood and plasma for method development were obtained from the University Clinical Centre, Ljubljana, Slovenia.

The study has been approved by the Slovenian National Medical Ethics Committee (Grant Nr.: 96/10/09).

The study was conducted at the Gynaecology and Obstetric Hospital Kranj. A written informed consent was obtained from all participants. Inclusion criteria were: age above 18 years, expressed request for pain relief other than epidural analgesia, gestation period of at least 35 weeks, body weight $50\text{--}100 \text{ kg}$, spontaneous or induced delivery, singleton term pregnancy, healthy status of parturient and fetus with normal cardiac function and cephalic presentation. Exclusion criteria were: allergy to opioid analgesics, age below 18 years, diabetes mellitus, pre-eclampsia, heart, liver, or kidney disease, twins, intrauterine growth retardation with estimated foetus weight below 2500 g , pathological cardiotocography (CTG), and fetal distress from whatever reason.

Two parturients (and their two neonates after delivery) were enrolled in the study. The maternal arterial blood in Case 1 was sampled just after the birth by direct arterial puncture. In Case 2 maternal blood sampling was omitted due to obstetric intervention after birth. All umbilical arterial and venous blood were sampled immediately after cord clamping. All samples were collected in standardized syringes for arterial blood gas analysis with anticoagulant (2.2 mL).

The remifentanil administration was in case 1, bolus doses of $0.41 \mu\text{g kg}^{-1}$ with a basal infusion of $0.026 \mu\text{g kg}^{-1} \text{ min}^{-1}$. In case 2, the bolus doses were $0.31 \mu\text{g kg}^{-1}$ with basal infusion of $0.019 \mu\text{g kg}^{-1} \text{ min}^{-1}$. The bolus doses were administered over 30 s intervals with 2 min lockout periods. The PCA was stopped at the beginning of the expulsion phase and vital functions were constantly monitored. The time from PCA termination until the delivery was noted as well as the time between the delivery and cord clamping with blood sampling.

Preparation of calibration and quality control (QC) samples

Blood calibrators were prepared by spiking standard solutions (25 μL) into 465 μL of blank blood, which was stabilized by the addition of 10 μL of 50 % (*m/V*) citric acid solution to inhibit the plasma esterases. The calibration samples were prepared with concentrations ranging from 0.15 to 40 ng mL^{-1} . The method's linear range with appropriate accuracy and precision has been validated between 0.3 and 40 ng mL^{-1} . For extraction procedure optimization in terms of achieving the highest recovery, plasma and dried plasma spots were used instead of blood and dried blood spots because of their better availability and easier handling. The method validation as well as sampling was performed only with blood. Plasma calibrators and QC samples for method optimization were prepared in a similar fashion but from separate standard weighing. The quality control samples at low, medium, and high levels were prepared in the following final concentrations: 1, 15, and 30 ng mL^{-1} , respectively. Using a repeater pipette, 20 μL blood samples in triplicates were applied to Whatman 903 DBS cards.

Sample collection

The Whatman 903 DBS cards for study samples were pretreated with 10 μL of 50 % citric acid and dried overnight. After cord clamping, using a repeater pipette, 20 μL aliquots of blood study samples were applied onto the same marked spots on Whatman DBS cards.

After two hours of drying time at room temperature, the cards were stored in air-tight bags with desiccant until analysis.

Sample preparation

The whole DBS was cut out and extracted with 500 μL of mixture water: methanol 1:1, with added 1 % formic acid (*V/V*), and 50 μL of internal standard solution (50 ng mL^{-1}). During optimization of the extraction procedure, several different solid phase extraction sorbents were tested for recovery: Ostro[®] 96 (Waters), HybridSPE[®] (Supelco), Strata[®]-X




Fig. 2. Remifentanyl recoveries (with RSD) obtained during the testing of different sorbents for the optimization of the sample preparation procedure.

(Phenomenex), BondElut Plexa[®] (Agilent), and Oasis[®] MCX (Waters). The highest recovery of more than 80 % was achieved with the Strata-X sorbent (Fig. 2) using the following extraction procedure: conditioning: 1 mL of methanol, and 1 mL water, loading the diluted sample with 1.5 mL of water, washing with 1 mL water, 1 mL 10 % methanol and 0.5 mL of 20 % methanol in water, drying for 10 min at maximum vacuum, elution with 1 mL methanol. The samples were then dried under a gentle stream of nitrogen at room temperature and reconstituted with 50 μ L of 10 % acetonitrile in a 0.1 % solution of formic acid.

Liquid chromatography-tandem mass spectrometry (LC-MS/MS)

The reconstituted samples were subjected to analysis by UHPLC Agilent 1290 coupled to an Agilent 6460 triple quadrupole mass spectrometer. 3 μ L were injected onto a 100 \times 3 mm Kinetex C₁₈ column (2.6 μ m particles) at 50 °C and eluted with mobile phase A (0.1 % formic acid in water), and B (acetonitrile) at 0.65 mL min⁻¹ using the following linear gradient (time [min], %B): (0,10); (0.25,10); (1.25,20); (2.40,30); (2.8,50); (3.4,90); (4.0,10). The total run time was 5.4 min. For MS detection, an ESI JetStream[®] interface in positive mode was used. The following mass transitions (MRMs) were monitored (parent \rightarrow daughter *m/z*; collision energy): remifentanyl: 377.2 \rightarrow 317.2; 8 eV, IS: 383.4113.0; 25 eV (Fig. 3).

Method validation

The method was checked according to the recommendations for validation of DBS methods (27), and included the following validation parameters: accuracy, precision, selectivity, extraction recovery, absolute and relative matrix effect, linear range, the lower limit of quantification, and stability under the predicted sample storage conditions.

RESULTS AND DISCUSSION

The method has been successfully developed and validated according to the purposes of our study.

Selectivity

The selectivity was determined by visual inspection of 6 processed blank matrix samples, where no interfering peaks were evident, apart from clearly observable, but not considered as problematic, chromatographic system-related carry-over of approximately 0.4 %. Nevertheless, even such a low carryover can represent up to 30 % of the response of the LLOQ sample (Fig. 3) when a blank extract is injected after a QC-high sample. However, this carry-over was not considered problematic since it is easily solved by a double sample injection.

Sensitivity and linear range

The limit of quantitation was established at 0.3 ng mL⁻¹, where good accuracy of 92 %, as well as acceptable precision of 18 % RSD, and a signal-to-noise ratio above 20:1 was achieved. The method response showed good linearity on a wide concentration range from 0.3 to 40 ng mL⁻¹ with a high determination coefficient ($R^2 > 0.999$).

Accuracy, precision, recovery, and matrix effect

Assay accuracy, precision, recovery, and matrix effect data are presented in Table I, and the calibration plot in Fig. 4. Absolute matrix effect and recovery were determined by comparison of instrumental responses obtained from neat solutions (A), post-spiked (B), and pre-spiked (C) samples at concentration levels of QC-low, and QC-high samples. The absolute matrix effects, calculated as $(B/A-1)*100\%$, and recovery $(C/B*100\%)$, were repeatable and comparable between high and low QC samples (Table I). The relative matrix effect was determined to be insignificant as the variability of the regression line slopes obtained in six different lots of blood, was 3.5 % RSD; an acceptable value is under 3–4 % RSD (22), therefore the method can be considered as free from significant relative matrix effects, which was expected due to the use of the isotope-labelled internal standard.

Table I. Accuracy, precision, recovery, and absolute matrix effect determined on QC samples

	Nominal conc. (ng mL ⁻¹)	Intraday precision (% RSD)	Interday precision (% RSD)	Bias (%)	Recovery (%)	Absolute matrix effect (%)
QC-Low	1.0	2.6	6.4	-10.1	83	-19
QC-Medium	15.0	3.5	3.9	2.4	n.d.	n.d.
QC-High	30.0	1.6	5.7	8.8	82	-21

n.d. – not determined

Stability

The stability testing of DBS samples stored at various conditions has shown less than 10 % deviation from their initial values which indicates that the analyte is stable at all three tested temperatures (-20, 24, and 40 °C) for at least a period of 14 days. The reported remifentanyl half-life in blood *ex vivo* is 99 ± 6 min (23, 24), therefore the stability of blood samples before being applied onto the pre-treated DBS cards should not be considered problematic if the sample is applied to a pre-treated blank DBS card with citric acid immediately after blood withdrawal or at least in a reasonably short time thereafter. Indeed, by testing consecutively prepared DBS samples within 4 minutes in 30 s intervals for each QC level we have not detected any observable analyte peak response deterioration. The stock solution and autosampler stability studies indicated that remifentanyl and IS solutions were stable for at least 48 hours at 4 °C.

DBS-specific validation parameters

Some of the recommended validation parameters according to the recent DBS-related guidelines were not determined because they were not applicable to the present study (25, 26). For example, the spot homogeneity, and effects of the spot volume and haematocrit were not tested because the blood samples were applied using a repeater pipette (with a fixed volume of 20 µL) and after drying, the whole spot was excised, thereby eliminating all issues regarding the spot concentration or inhomogeneity (27). Furthermore, the effect




Fig. 3. Left-hand side: A representative SRM chromatogram of an LLOQ sample (light grey trace) compared to an extracted blank sample (dark grey trace). Right-hand side: A representative parturient sample with MRM chromatograms for remifentanyl-¹³C₆ (top) and remifentanyl (bottom).

of haematocrit on analyte recovery could not be performed due to the rapid analyte breakdown in blood incubation conditions usually employed for such a test (gentle shaking at 37 °C, 30–45 min). Even though the neonates are known to have higher and variable haematocrit (28), minimal effects of differences in haematocrit on remifentanyl recovery are expected since the red blood cell-to-plasma ratio for remifentanyl is 0.89, which is close to unity, therefore a change in haematocrit would not lead to any significant differences in remifentanyl partitioning (29, 30). Furthermore, since our results show high recovery from the whole blood spots (Table I) and comparable recovery from dried plasma spots (data not shown), also the extraction recovery should remain unaffected with varying haematocrit.

The results from our pilot study are shown in Table II. There, the measured concentrations of remifentanyl in all tested samples were significantly lower than 1–3 ng mL⁻¹, where (minimal) adverse effects on ventilation may be expected. However, when considering the time of sampling and extrapolation of remifentanyl concentration to the delivery time, using a context-sensitive half-life of 3.5 min (31, 32), the estimated maternal arterial concentration gets close to the above-mentioned threshold interval in the case (1) of the maternal arterial sample (0.91 ng mL⁻¹, Table II). The neonatal arterial blood concentrations were all below the limit of quantitation (0.3 ng mL⁻¹) but were reported nevertheless as semi-quantitative or estimated values. For the calculation of the estimated neonatal remifentanyl concentration at the time of delivery, the same context-sensitive half-life of 3.5 min was used for the mothers even though an interval as high as 3.4–5.7 min was reported for all paediatric age groups (32). The reasoning for the decision to use the lower




Fig. 4. The calibration line for remifentanyl in human dried blood spots; the relative response (y-axis) is the ratio between the peak area of remifentanyl and that of $^{13}\text{C}_6$ remifentanyl (IS). Closed diamonds represent the calibrators, while the open triangles represent the QCs; weight: $1/c$. The enlarged section outlined by the dashed line from 0 to 12 ng mL^{-1} demonstrates linear response down to the lower limit of quantitation.

half-life was to be able to recognize with greater sensitivity the conditions possibly leading to remifentanyl adverse effects due to the higher calculated extrapolated concentrations at the time of delivery.

Table II. The determined and estimated remifentanyl concentrations in maternal and umbilical cord blood samples

Sample	Time from PCA stop until delivery (min)	Time of sampling after delivery (min)	Relative MS response (analyte/IS)	Measured remifentanyl concentration (ng mL^{-1})	Estimated remifentanyl concentration at the time of delivery (ng mL^{-1})
MAT-ART, case 1	3	3	0.007678	0.50	0.91
UMB-ART, case 1	3	2	0.003501	0.13 ^a	0.19 ^a
UMB-VEN, case 1	3	2	0.006307	0.38	0.56
UMB-ART, case 2	7	5	0.003152	0.10 ^a	0.27 ^a
UMB-VEN, case 2	7	5	0.004698	0.23 ^a	0.62 ^a

^a Estimated value, due to the concentration being below the limit of quantitation (0.3 ng mL^{-1}).

MAT – maternal, UMB – neonatal umbilical, ART – arterial, VEN – venous sample.

When comparing our results to a similar study by Shen *et al.* (8), where the mean maternal arterial remifentanyl concentration in the PCA group was 4.95 ng mL^{-1} , and the mean umbilical venous concentration was 2.98 ng mL^{-1} , a significant difference to our findings can be observed. At first, the disagreement between the results seems difficult to explain, since the bolus doses in PCA groups in both studies were similar: $0.31\text{--}0.4 \mu\text{g kg}^{-1}$ administered over 30 s with 2 min lockout periods, which can be regarded as comparable, especially when considering also the basal infusion in our study $0.019\text{--}0.026 \mu\text{g kg}^{-1} \text{ min}^{-1}$ (8). However, the main difference between our results (Table II) and the above-cited concentrations can be attributed to dissimilarity in the duration of the PCA remifentanyl administration relative to the delivery and blood sampling time point. In our study, the PCA was stopped at the beginning of the expulsion phase, whereas in the study by Shen *et al.*, the PCA had been enabled throughout the expulsion phase until the delivery, and the time from the last bolus to sampling was only 74 s in average, which coincides with the estimated remifentanyl peak blood concentration (8). Therefore, in our study, the observed significantly lower maternal and neonatal remifentanyl concentrations after delivery can be attributed predominantly to the longer period without PCA before the expulsion phase, delivery, and blood sampling. The cumulative amount of time after the last bolus until our sampling would sum up to 5–12 minutes (Table II), enough to account for the significant remifentanyl concentration drop with the context-sensitive half-life below 3.5 min. The lower concentrations at the time of delivery would also mean a safer and more conservative pain management strategy due to the lower probability of adverse events, especially in the neonate, but in the mothers as well.

Finally, the presented method, albeit applied only to a very limited number of samples in our small pilot study, has been proven sensitive enough for the safety assessment of newer remifentanyl administration protocols employing only $0.4 \mu\text{g kg}^{-1}$ bolus doses. The found concentration levels were all below the threshold of expected adverse drug effects of $1\text{--}3 \text{ ng mL}^{-1}$, even when extrapolated to the time of delivery (Table II). Our results go hand-in-hand with the recent findings of a large meta-analysis which compared the remifentanyl PCA with epidural analgesia during labour and found no differences in Apgar scores < 7 at 5 minutes in both groups, although the incidence of respiratory depression was nevertheless significantly higher in the PCA group (33). It is important to note that our analytical method can measure remifentanyl in a wide concentration range, from the sub-therapeutic 0.3 ng mL^{-1} to toxic 40 ng mL^{-1} . The large working range may be useful also for other remifentanyl applications, not only for labour analgesia. Significantly higher concentrations compared to our pilot study can be expected also in other remifentanyl PCA protocols as demonstrated in the study by Shen *et al.* (8) since in some practices, and possible future efficacy/safety studies, the administration of remifentanyl is used or expected to last through the whole delivery, particularly throughout the expulsion phase, where effective pain control is also most needed and desired, resulting in much higher blood concentrations of remifentanyl at the time of delivery. This applies to neonatal and maternal samples whose concentrations are expected to be approximately two-fold higher than that of the neonates, and hence, the mothers might be at higher risk of serious adverse events (1, 18, 33), underlining the need for appropriate dose-finding studies combined with individualization based on clinical assessment. Other venous and capillary blood sampling methods could also be used in conjunction with our analytical methods, such as volumetric absorptive microsampling (VAMS) (34), finger-prick (35), and heel-prick sampling (36).

CONCLUSIONS

The presented method has proven to be sensitive enough for remifentanyl non-invasive umbilical cord blood level determination to support the needed efficacy and safety trials because it offers a limit of quantitation as low as 0.3 ng mL⁻¹. This is 3-fold lower than the concentration at which the respiratory and cardiac depression could occur, which no other method for the determination of remifentanyl in dried blood spots has been able to achieve to date.

Our small pilot study has shown that the method presented here is sensitive enough to accurately measure the levels of remifentanyl in both mother and newborn blood samples that are relevant for its safety estimation, even when the PCA is stopped several minutes before the expulsion phase.

Most importantly, our developed method represents a very useful and simple sampling procedure that does not represent any additional burden for the newborn, requires minimal sample handling by personnel, and solves the analyte instability in blood. However, to be suitable for larger-scale efficacy and safety studies of remifentanyl in various settings, the method should be tested also in capillary blood obtained by heel-prick and finger-prick sampling consequently allowing even broader implementation.

Acknowledgments. – The authors are thankful to Mr. Erik Tičar, MPharm., for his help with the sample preparation.

Funding. – The study has been supported by the Slovenian Research Agency (ARIS) (P1-0189).

Conflicts of interest. – The authors declare no conflict of interest.

Authors contributions. – Conceptualization, J.T., A.R., and A.M.; methodology, J.T., A.R., and A.M.; investigation, A.R.; analysis, J.T.; writing, original draft preparation, J.T., A.R., and A.M.; writing, review and editing, J.T., A.R., and A.M. All authors have read and agreed to the published version of the manuscript.

REFERENCES

1. K. Fresenius LLC, Remifentanyl hydrochloride for injection, for intravenous use. Highlights of prescribing information. NDA 20-630/S-005 Page 3 – Ultiva – Accessdata.fda.gov.
2. J. Wise, Maternity care: Remifentanyl is recommended as alternative to epidural in draft guidance, *BMJ* 381 (2023) Article ID 946; <https://doi.org/10.1136/bmj.p946>
3. S. Suarez-Easton, O. Erez, N. Zafran, J. Carmeli, G. Garimi and R. Salim, Pharmacologic and non-pharmacologic options for pain relief during labor: an expert review, *Am. J. Obstet. Gynecol., Labor and Delivery at Term – Part One: Partograms, Labor Disorders, Analgesia/Anesthesia, and Fever* 228(5, Supplement) (2023) S1246–S1259; <https://doi.org/10.1016/j.ajog.2023.03.003>
4. A. Schnabel, N. Hahn, J. Broscheit, R. M. Muellenbach, L. Rieger, N. Roewer and P. Kranke, Remifentanyl for labour analgesia: a meta-analysis of randomised controlled trials, *Eur. J. Anaesthesiol.* 29(4) (2012) 177–185; <https://doi.org/10.1097/EJA.0b013e32834fc260>
5. A. A. Melber, Y. Jelting, M. Huber, D. Keller, A. Dullenkopf, T. Girard and P. Kranke, Remifentanyl patient-controlled analgesia in labour: six-year audit of outcome data of the RemiPCA SAFE Network (2010–2015), *Int. J. Obstet. Anesth.* 39 (2019) 12–21; <https://doi.org/10.1016/j.ijoa.2018.12.004>
6. P. Muddangula, H. S. Tan, C. W. Tan, W. L. Leong, R. Sultana and B. L. Sng, Satisfaction and outcomes with patient-controlled intravenous analgesia of remifentanyl for labor analgesia at a spe-

- cialist maternity hospital in Singapore: A retrospective observational study, *Bali J. Anesthesiol.* 7(2) (2023) Article ID 105 (6 pages); https://doi.org/10.4103/bjoa.bjoa_52_23
7. N. Jenkins, M. Garry and E. Lewis, *Guideline For Remifentanyl Patient Controlled Analgesia (PCA) For Labour*. Anaesthetics Dept / Labour Ward Forum, NHS Wales; Retrieved from <https://wisdom.nhs.wales/health-board-guidelines/swansea-bay-maternity-file/patient-controlled-analgesia-pca-for-labour-guideline-for-remifentanyl-swansea-bay-maternity-guideline-2021-pdf/>
 8. M. K. Shen, Z. F. Wu, A. B. Zhu, L. L. He, X. F. Shen, J. J. Yang and S. W. Feng, Remifentanyl for labour analgesia: a double-blinded, randomised controlled trial of maternal and neonatal effects of patient-controlled analgesia versus continuous infusion, *Anaesthesia* 68(3) (2013) 236–244; <https://doi.org/10.1111/anae.12098>
 9. J. Coonen, M. Marcus, E. Joosten, M. van Kleef, C. Neef, H. van Aken and W. Gogarten, Transplacental transfer of remifentanyl in the pregnant ewe: Remifentanyl in the pregnant ewe, *Br. J. Pharmacol.* 161(7) (2010) 1472–1476; <https://doi.org/10.1111/j.1476-5381.2010.00783.x>
 10. I. Ronel and C. F. Weiniger, A broadening choice for labor analgesia: remifentanyl on the á la carte menu, *Int. J. Obstet. Anesth.* 39 (2019) 1–6; <https://doi.org/10.1016/j.ijoa.2019.06.005>
 11. M. Van de Velde and B. Carvalho, Remifentanyl for labor analgesia: an evidence-based narrative review, *Int. J. Obstet. Anesth.* 25 (2016) 66–74; <https://doi.org/10.1016/j.ijoa.2015.12.004>
 12. P.-Y. Dewandre, SP22.1 Remifentanyl PCIA has no place in labor analgesia, *Reg. Anesth. Amp. Pain Med.* 47(Suppl 1) (2022) Article ID A21 (4 pages); <https://doi.org/10.1136/rapm-2022-ESRA.24>
 13. E. E. Sharpe and M. D. Rollins, Beyond the epidural: Alternatives to neuraxial labor analgesia, *Best Pract. Res. Clin. Anaesthesiol.* 36(1) (2022) 37–51; <https://doi.org/10.1016/j.bpa.2022.04.005>
 14. R. Marr, J. Hyams and V. Bythell, Cardiac arrest in an obstetric patient using remifentanyl patient-controlled analgesia, *Anaesthesia* 68(3) (2013) 283–287; <https://doi.org/10.1111/anae.12099>
 15. M. A. O. Kinney, C. H. Rose, K. D. Traynor, E. Deutsch, H. U. Memon, S. Tanouye, K. W. Arendt and J. R. Hebl, Emergency bedside cesarean delivery: lessons learned in teamwork and patient safety, *BMC Res. Notes* 5(1) (2012) Article ID 412 (5 pages); <https://doi.org/10.1186/1756-0500-5-412>
 16. C. Pruefer and A. Bewlay, Respiratory arrest with remifentanyl patient-controlled analgesia – another case: Correspondence, *Anaesthesia* 67(9) (2012) 1044–1045; <https://doi.org/10.1111/j.1365-2044.2012.07273.x>
 17. J. C. Bonner and W. McClymont, Respiratory arrest in an obstetric patient using remifentanyl patient-controlled analgesia, *Anaesthesia* 67(5) (2012) 538–540; <https://doi.org/10.1111/j.1365-2044.2011.06997.x>
 18. S. L. M. Logtenberg, M. L. Vink, M. B. Godfried, I. C. M. Beenackers, F. G. Schellevis, B. W. Mol and C. J. Verhoeven, Serious adverse events attributed to remifentanyl patient-controlled analgesia during labour in The Netherlands, *Int. J. Obstet. Anesth.* 39 (2019) 22–28; <https://doi.org/10.1016/j.ijoa.2018.10.013>
 19. V. C. Ziesenitz, J. D. Vaughns, G. Koch, G. Mikus and J. N. van den Anker, Pharmacokinetics of fentanyl and its derivatives in children: A comprehensive review, *Clin. Pharmacokinet.* 57(2) (2018) 125–149; <https://doi.org/10.1007/s40262-017-0569-6>
 20. A. Maroni, M.-S. Aubelle and C. Chollat, Fetal, preterm, and term neonate exposure to remifentanyl: A systematic review of efficacy and safety, *Pediatr. Drugs* 25(5) (2023) 537–555; <https://doi.org/10.1007/s40272-023-00583-w>
 21. M. Massano, C. Incardona, E. Gerace, P. Negri, E. Alladio, A. Salomone and M. Vincenti, Development and validation of a UHPLC-HRMS-QTOF method for the detection of 132 new psychoactive substances and synthetic opioids, including fentanyl, in dried blood spots, *Talanta* 241 (2022) Article ID 123265; <https://doi.org/10.1016/j.talanta.2022.123265>
 22. B. K. Matuszewski, Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis, *J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci.* 830(2) (2006) 293–300; <https://doi.org/10.1016/j.jchromb.2005.11.009>
 23. P. J. Davis, R. L. Stiller, A. S. Wilson, F. X. McGowan, T. D. Egan and K. T. Muir, In vitro remifentanyl metabolism: The effects of whole blood constituents and plasma butyrylcholinesterase, *Anesth. Analg.* 95(5) (2002) Article ID 1305 (3 pages); <https://doi.org/10.1097/00000539-200211000-00038>

24. R. A. Koster, H. E. M. Vereecke, B. Greijdanus, D. J. Touw, M. M. R. F. Struys and J. W. C. Alffenaar, Analysis of remifentanyl with liquid chromatography-tandem mass spectrometry and an extensive stability investigation in EDTA whole blood and acidified EDTA plasma, *Anesth. Analg.* **120**(6) (2015) Article ID 1235 (7 pages); <https://doi.org/10.1213/ANE.0000000000000643>
25. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), *ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf*; Retrieved from https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf
26. S. Capiou, H. Veenhof, R. A. Koster, Y. Bergqvist, M. Boettcher, O. Halmingh, B. G. Keevil, B. C. P. Koch, R. Linden, C. Pistos, L. M. Stolk, D. J. Touw, C. P. Stove and J.-W. C. Alffenaar, Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and validation of dried blood spot-based methods for therapeutic drug monitoring, *Ther. Drug Monit.* **41**(4) (2019) Article ID 409 (22 pages); <https://doi.org/10.1097/FTD.0000000000000643>
27. N. G. L. Jager, H. Rosing, J. H. M. Schellens and J. H. Beijnen, Procedures and practices for the validation of bioanalytical methods using dried blood spots: a review, *Bioanalysis* **6**(18) (2014) 2481–2514; <https://doi.org/10.4155/bio.14.185>
28. C. Dausani, V. Karalis, Y. L. Loukas, K. H. Schulpis, K. Alexiou and Y. Dotsikas, Dried blood spots in neonatal studies: A computational analysis for the role of the hematocrit effect, *Pharmaceuticals* **16**(8) (2023) Article ID 1126 (16 pages); <https://doi.org/10.3390/ph16081126>
29. L. Van Hese, T. Theys, A. R. Absalom, S. Rex and E. Cuypers, Comparison of predicted and real propofol and remifentanyl concentrations in plasma and brain tissue during target-controlled infusion: a prospective observational study, *Anaesthesia* **75**(12) (2020) 1626–1634; <https://doi.org/10.1111/anae.15125>
30. M. Kabbaj, P. Vachon and F. Varin, Impact of peripheral elimination on the concentration-effect relationship of remifentanyl in anaesthetized dogs, *Br. J. Anaesth.* **94**(3) (2005) 357–365; <https://doi.org/10.1093/bja/aei058>
31. J. Park and J.-Y. Kwon, Remifentanyl or dexmedetomidine for monitored anesthesia care during cataract surgery under topical anesthesia, *Korean J. Anesthesiol.* **63**(1) (2012) 92–93; <https://doi.org/10.4097/kjae.2012.63.1.92>
32. A. K. Ross, P. J. Davis, G. deL Dear, B. Ginsberg, F. X. McGowan, R. D. Stiller, L. G. Henson, C. Huffman and K. T. Muir, Pharmacokinetics of remifentanyl in anesthetized pediatric patients undergoing elective surgery or diagnostic procedures, *Anesth. Analg.* **93**(6) (2001) Article ID 1393 (9 pages); <https://doi.org/10.1097/00000539-200112000-00008>
33. X. Lei, Y. Yu, M. Li, P. Fang, S. Gan, Y. Yao, Y. Zhou and X. Kang, The efficacy and safety of remifentanyl patient-controlled versus epidural analgesia in labor: A meta-analysis and systematic review, *PLoS One* **17**(12) (2022) e0275716 (14 pages); <https://doi.org/10.1371/journal.pone.0275716>
34. M. Protti, P. M. Sberna, R. Sardella, T. Vovk, L. Mercolini and R. Mandrioli, VAMS and StAGE as innovative tools for the enantioselective determination of clenbuterol in urine by LC-MS/MS, *J. Pharm. Biomed. Anal.* **195** (2021) Article ID 113873 (8 pages); <https://doi.org/10.1016/j.jpba.2020.113873>
35. J. Sikonja, J. Brecelj, M. Zerjav Tansek, B. Repic Lampret, A. Drole Torkar, S. Klemencic, N. Lipovec, V. Stefanova Kralj, S. Bertok, J. Kovac, B. Faganel Kotnik, M. Tesarova, Z. I. Remec, M. Debeljak, T. Battelino and U. Groselj, Clinical and genetic characteristics of two patients with tyrosinemia type 1 in Slovenia – A novel fumarylacetoacetate hydrolase (FAH) intronic disease-causing variant, *Mol. Genet. Metab. Rep.* **30** (2022) Article ID 100836 (7 pages); <https://doi.org/10.1016/j.ymgmr.2021.100836>
36. D. Perko, B. Repic Lampret, Z. I. Remec, M. Zerjav Tansek, A. Drole Torkar, B. Krhin, A. Bicek, A. Oblak, T. Battelino and U. Groselj, Optimizing the phenylalanine cut-off value in a newborn screening program, *Genes* **13**(3) (2022) Article ID 517 (12 pages); <https://doi.org/10.3390/genes13030517>